Roughly 132,000 people in the United States are affected by IPF, and that number continues to grow with 30,000-40,000 new cases each year.
Source: U.S. National Library of Medicine. (2020, July 1). Idiopathic pulmonary fibrosis. MedlinePlus. Retrieved May 10, 2022, from https://medlineplus.gov/genetics/condition/idiopathic-pulmonary-fibrosis/#frequency
Affecting between 13-20 per 100,000 people worldwide, the disease is more common in people who are 50 years of age or older. More men are affected than women.
Because IPF is a disease that causes scarring in the lung, it mostly affects respiratory function. Common symptoms with IPF are:
These symptoms may be mild or nonexistent at the start of your diagnosis but are likely to worsen as the disease progresses.
What are my options?
You can explore any of the treatment plans below with your care team to find out what works best for you depending on your stage of IPF.
What help can Endeavor Offer?
Endeavor is conducting a Phase 2 clinical trial to study our investigational therapy, ENV-101, to potentially help better the lives of those who are living with IPF. ENV-101 acts on a protein in the body that is thought to be involved in the scarring of the lungs. By blocking this process, ENV-101 may slow progression of the disease, which may improve the symptoms of IPF.